


## Amendments to the Claims:

1. (Currently amended) A compound of the formula:



and the or a pharmaceutically acceptable salts, ~~hydrates, and prodrugs~~ thereof, wherein;

- a) R¹ is represented by ~~halogen~~, (C₁-C₂)alkyl, substituted with one or more halogens, or (C₁-C₂)alkoxy, substituted with one or more halogens,
- b) R² is represented by hydrogen or halogen,
- c) X¹ and X² are each independently represented by
  - i) (C₁-C₁₂)alkyl, optionally substituted,
  - ii) (C₂-C₁₂)alkenyl, optionally substituted,
  - iii) (C₂-C₁₂)alkynyl, optionally substituted,
  - iv) (C₃-C₁₀)cycloalkyl, optionally substituted,
  - v) (C₃-C₁₀)cycloalkyl(C₁-C₆)alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted,
  - vi) (C₆-C₁₀)aryl, optionally substituted,
  - vii) (C₆-C₁₀)aryl(C₁-C₆)alkyl, in which both the alkyl and aryl moieties may be optionally substituted,
  - viii) -(CH₂)q-CH₂-ZH, in which Z is S or O and q is an integer from 1-11,
  - ix) -(CH₂)n-Y-(CH₂)p-CH₃, in which Y is O or S, n is an integer from 1 to 4, and p is an integer from 1 to 4,
  - x) -[CH₂]m-C(O)R³, in which m is an integer selected from 1 to 8 and R³ is represented by hydrogen, (C₁-C₁₂)alkyl, (C₆-C₁₀)aryl, or (C₆-

- C<sub>10</sub>)aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which both the alkyl and aryl moieties may be optionally substituted,
- xi) -[CH<sub>2</sub>]<sub>m</sub>-C(O)-O-R<sup>4</sup>, in which m is as defined above and R<sup>4</sup> is represented by hydrogen, (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, or (C<sub>6</sub>-C<sub>10</sub>)aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the alkyl and aryl moieties may be optionally substituted,
  - xii) -[CH<sub>2</sub>]<sub>m</sub>-C(O)-NR<sup>5</sup>R<sup>6</sup> in which m is as described above, and R<sup>5</sup> and R<sup>6</sup> are each independently represented by hydrogen, (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, or (C<sub>6</sub>-C<sub>10</sub>)aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the alkyl and aryl moieties may each be optionally substituted,
    - i) heteroaryl, optionally substituted,
    - ii) heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the heteroaryl and alkyl moieties may each be optionally substituted,
    - iii) heterocyclic, optionally substituted, or,
    - iv) heterocyclic(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the alkyl and heterocyclic moieties may each be optionally substituted.
2. (Original) A compound according to claim 1 in which R<sup>1</sup> is represented by trifluoromethyl.
  3. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] 4** ~~or 2~~ in which said trifluoromethyl is located at the 4-position of the pyridine ring.
  4. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] 1-3** ~~2~~ in which R<sup>2</sup> is hydrogen.
  5. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] [[1-4]]2** in which X<sup>1</sup> is (C<sub>1</sub>-C<sub>[[12]]<sub>12</sub></sub>)alkyl and X<sub>[[2]]<sup>2</sup> is (C<sub>[[6]]<sub>6</sub></sub>-C<sub>[[10]]<sub>10</sub></sub>)aryl(C<sub>[[1]]<sub>1</sub></sub>-C<sub>[[6]]<sub>6</sub></sub>)alkyl.</sub>
  6. (Currently amended) A compound according to ~~any one of claim~~ **[[s]] [[1-5]]2** in which X<sup>1</sup> and X<sup>2</sup> are each (C<sub>1</sub>-C<sub>12</sub>)alkyl


7. (Currently amended) A compound according to ~~anyone of claim~~ ~~[[s]]~~ ~~[[1-6]]~~ ~~2~~ in which  $X^1$  is  $(C_1-C_{12})$ alkyl and  $X^{[2]}$  is  $(C^{[3]}_3-C^{[10]}_{10})$ cycloalkyl( $C^{[1]}_1-C^{[6]}_6$ )alkyl.
  
8. (Original) A compound according to claim 1 selected from the group consisting of  
 ( R )-(+)- 6-[Methyl-(1-Phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
 ( R )-(+)-2-Chloro-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
 6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
 6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethoxy-nicotinonitrile,  
 6-[methyl-(1-(4-fluorophenyl)-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
 6-[methyl-(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
 6-[butyl(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethoxy-nicotinonitrile,  
 6-dipropylamino-4-trifluoromethyl-nicotinonitrile,  
 2-chloro-6-dimethylamino-4-trifluoromethyl-nicotinonitrile,  
 6-(hexyl-octyl-amino)-4-trifluoromethyl-nicotinonitrile,  
 6-(sec-butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,  
 6-[butyl-(2-hydroxy-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
 6-(butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,  
 6-(benzyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,  
 6-(cyclohexyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,  
 6-(cyclopropylmethyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,  
 6-(sec-butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile,  
 6-Dipropylamino-2-chloro-4-trifluoromethyl-nicotinonitrile,  
 6-(propyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile, and,  
 6-(Butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile.
  
9. (Currently amended) Use of a compound according to ~~anyone of Claim~~ ~~[[s]]~~ ~~1~~ ~~[[8]]~~ as a medicine.
  
10. (Currently amended) ~~Use of a compound according to anyone of Claims 1-8 in the manufacture of a medicament~~ A method for inhibiting activation of the androgen receptor ~~[[.]]~~ , comprising, administering a compound according to Claim 1 to a patient in need thereof.

11. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of Claim[[s]] 1[[--8]]~~ in admixture with 1, or more, pharmaceutically acceptable excipients.
12. (Currently amended) A topical pharmaceutical formulation comprising a compound according to ~~any one of Claim[[s]] 1[[--8]]~~ in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.
13. (Currently amended) ~~An article of manufacture~~ A kit comprising a compound according to ~~any one of Claim[[s]] 1[[--8]]~~ packaged for retail distribution which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.
14. (Currently amended) ~~Use of a compound according to any one of claims 1-8 in the manufacture of a medicament for alleviating~~ A method of treating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia comprising the administration of a compound according to claim 1.

Date:

5/18/06

Respectfully submitted,

By   
J. Michael Dixon  
Reg. No. 32,410  
Tel.: (734) 622-1705  
Fax: (734) 622-1553